The National Institute of Allergy and Infectious Diseases (NIAID) director specifically detailed the call for pan-coronavirus candidates and mucosal options that can be given to patients intranasally, all the while reinforcing that “innovative approaches are clearly needed to induce broad and durable protection against coronaviruses known and unknown”.
The US Food and Drug Administration (FDA) gave a recommendation at the end of June, encouraging vaccine manufacturers like Moderna and Pfizer to continue pushing on with Omicron targeting formulations, with the aim of making the vaccines available in autumn this year.
